Provided by Tiger Fintech (Singapore) Pte. Ltd.

Redhill Biopharma

2.17
-0.0900-3.98%
Post-market: 2.10-0.0700-3.23%18:08 EDT
Volume:172.60K
Turnover:358.93K
Market Cap:3.80M
PE:-0.32
High:2.25
Open:2.01
Low:1.96
Close:2.26
Loading ...

RedHill Biopharma Gets Nasdaq Noncompliance Notice

MT Newswires Live
·
18 Apr

RedHill Biopharma receives non-compliance letter from Nasdaq

TIPRANKS
·
18 Apr

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

PR Newswire
·
18 Apr

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

PR Newswire
·
16 Apr

Redhill Biopharma FY 2024 EPS $(0.00) Down From $0.01 YoY, Sales $8.04M Up From $6.53M YoY

Benzinga
·
10 Apr

Press Release: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Dow Jones
·
10 Apr

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

PR Newswire
·
27 Feb

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

PR Newswire
·
25 Feb

RedHill Biopharma Begins Phase 2 Study of Opaganib, Darolutamide for Advanced Prostate Cancer; Shares Rise

MT Newswires Live
·
04 Feb

RedHill Biopharma begins Phase 2 study of prostate cancer combination

TIPRANKS
·
04 Feb

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

PR Newswire
·
04 Feb

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

PR Newswire
·
21 Jan

RedHill Biopharma’s opaganib shows radioprotective activity in study

TIPRANKS
·
10 Dec 2024

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

PR Newswire
·
10 Dec 2024

RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court

TipRanks
·
03 Dec 2024

RedHill Biopharma Awarded $8 Million in Legal Case Against Kukbo

MT Newswires Live
·
02 Dec 2024

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

PR Newswire
·
02 Dec 2024

RedHill Biopharma to Present Opaganib at U.S. Defense Conference

TIPRANKS
·
28 Oct 2024